Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia : final results from the BFORE trial
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: 10.1038/s41375-022-01589-y
- Event
-
Veröffentlichung
- (where)
-
Aachen
- (who)
-
Universitätsbibliothek der RWTH Aachen
- (when)
-
2022
- Creator
-
Brümmendorf, Tim H.
Cortés, Jorge Eduardo
Milojkovic, Dragana
Gambacorti-Passerini, Carlo
Clark, Richard E.
le Coutre, Philipp
Garcia-Gutierrez, Valentin
Chuah, Charles
Kota, Vamsi
Lipton, Jeffrey H.
Rousselot, Philippe
Mauro, Michael J.
Hochhaus, Andreas
Hurtado Monroy, Rafael
Leip, Eric
Purcell, Simon
Yver, Anne
Viqueira, Andrea
Deininger, Michael W.
- DOI
-
10.18154/RWTH-2022-06825
- URN
-
urn:nbn:de:101:1-2022071303270299615870
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:50 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Brümmendorf, Tim H.
- Cortés, Jorge Eduardo
- Milojkovic, Dragana
- Gambacorti-Passerini, Carlo
- Clark, Richard E.
- le Coutre, Philipp
- Garcia-Gutierrez, Valentin
- Chuah, Charles
- Kota, Vamsi
- Lipton, Jeffrey H.
- Rousselot, Philippe
- Mauro, Michael J.
- Hochhaus, Andreas
- Hurtado Monroy, Rafael
- Leip, Eric
- Purcell, Simon
- Yver, Anne
- Viqueira, Andrea
- Deininger, Michael W.
- Universitätsbibliothek der RWTH Aachen
Time of origin
- 2022
Other Objects (12)
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia : results from the 24-month follow-up of the BELA trial
The Cytogenetic Landscape of Pediatric Chronic Myeloid Leukemia Diagnosed in Chronic Phase
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia
The impact of newly diagnosed chronic paediatric conditions on parental quality of life
Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment
Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment
Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
Somatic variant profiling in chronic phase pediatric chronic myeloid leukemia
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia : results from the 24-month follow-up of the BELA trial
The Cytogenetic Landscape of Pediatric Chronic Myeloid Leukemia Diagnosed in Chronic Phase
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia
The impact of newly diagnosed chronic paediatric conditions on parental quality of life
Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment
Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment
Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
Somatic variant profiling in chronic phase pediatric chronic myeloid leukemia
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia : results from the 24-month follow-up of the BELA trial
The Cytogenetic Landscape of Pediatric Chronic Myeloid Leukemia Diagnosed in Chronic Phase
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia
The impact of newly diagnosed chronic paediatric conditions on parental quality of life
Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment
Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment
Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
Somatic variant profiling in chronic phase pediatric chronic myeloid leukemia